Weight-loss drugs tied to lower fracture risk in diabetes patients, study finds
A large study indicates that GLP-1 weight-loss drugs like Ozempic may reduce the risk of bone fractures in patients with type 2 diabetes. The findings challenge previous concerns that these medications could negatively impact bone health.
Why it matters
This research provides critical health data for millions of diabetes patients and clarifies the safety profile of popular weight-loss medications.
Weight-loss drugs tied to lower fracture risk in diabetes patients, study finds GLP-1 medicines such as Ozempic may reduce the risk of serious bone fractures in people with type 2 diabetes, according to a large study that challenges fears the blockbuster drugs could damage bone health.
Researchers found that patients starting GLP-1 medicines had a 21% lower risk of fragility fractures over three years than comparable patients prescribed DPP-4 medicines — another class of diabetes medicines.
People with type 2 diabetes face an elevated fracture risk from low-energy trauma — such as falling from standing height or lower — despite often having normal or higher bone density. That "may be due to lower bone strength, impaired bone microarchitecture, and accelerated bone loss," the researchers said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in